AdARRC™
  • Call Us: +971 2 245 0058
  • Email Us : info@adarrc.org
  • Home
  • AdARRC™
    • About Us
    • Committee
    • Future Dates of AdARRC™
    • History
      • Previous Speakers of AdARRC™
      • AdARRC Academy™
      • AdARRC Summit™
    • Annual Initiatives
      • Best Image Competition
      • Nominate a Trainee Winner
  • Registration
    • Register Now
    • Venue & Accommodation
    • UAE Visa Application
  • Call for Abstracts
  • Best Image Competition
  • Nominate a Trainee
  • Scientific Agenda
  • Sponsorship
    • Sponosors
    • Become a Sponsor or Exhibitor
×

Author: AdARRC™

 Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed
AdARRC™ November 29, 2021 Monday Weekly Update

Recurrent herpes zoster more common in women, younger adults, and the immunosuppressed

Question What is the incidence and timing of recurrent herpes zoster in older adults? Conclusion The incidence of recurrent herpes zoster is comparable with the incidence of a first episode zoster infection, supporting the benefit of vaccination for individuals with…
Read More
 There is limited data on ivermectin in patients with COVID-19
AdARRC™ November 22, 2021 Monday Weekly Update

There is limited data on ivermectin in patients with COVID-19

Question Does ivermectin decrease mortality among persons hospitalized with COVID-19? Conclusion Although the data suggest that ivermectin decreases mortality among persons hospitalized with COVID-19, the messiness of the comparison groups and the concerns over data veracity indicate that more rigorous…
Read More
 Pregnant women who become ill with COVID-19 are more likely to die and have adverse perinatal and neonatal outcomes
AdARRC™ November 15, 2021 Monday Weekly Update

Pregnant women who become ill with COVID-19 are more likely to die and have adverse perinatal and neonatal outcomes

Question Do pregnant women who become ill with COVID-19 have worse outcomes than pregnant women who are not infected with COVID-19? Conclusion Pregnant women who become ill with COVID-19 are more likely to die and have adverse perinatal and neonatal…
Read More
 IL-6 antagonists may be associated with lower mortality in adults hospitalized with COVID-19
AdARRC™ November 8, 2021 Monday Weekly Update

IL-6 antagonists may be associated with lower mortality in adults hospitalized with COVID-19

Question Are interleukin-6 antagonists effective in decreasing mortality among persons hospitalized with COVID-19? Conclusion Based on this systematic review, it is unclear if IL-6 antagonists decrease mortality among persons hospitalized with COVID-19. Co-intervention with corticosteroids has muddied the waters, and…
Read More
 Intravenous immune globulin plus corticosteroids is the best initial therapy for multisystem inflammatory syndrome in children
AdARRC™ November 1, 2021 Monday Weekly Update

Intravenous immune globulin plus corticosteroids is the best initial therapy for multisystem inflammatory syndrome in children

Question What is the best treatment for multisystem inflammatory syndrome in children? Conclusion For children with MIS-C caused by SARS-CoV-2, the preferred initial treatment is IVIG plus corticosteroids. Reference Son MB, Murray N, Friedman K, et al, for the Overcoming…
Read More
 Vaccines are only slightly less effective against the delta variant
AdARRC™ October 25, 2021 Monday Weekly Update

Vaccines are only slightly less effective against the delta variant

Question How effective are current vaccines against the delta variant of SARS-CoV-2? Conclusion Fortunately, the existing Pfizer-BioNTech and Oxford-AstraZeneca vaccines appear to offer robust protection against the widespread delta variant. Efficacy is much better after 2 doses than after only…
Read More
 A single corticosteroid burst in children is associated with harms
AdARRC™ October 18, 2021 Monday Weekly Update

A single corticosteroid burst in children is associated with harms

Question Are steroid bursts in children potentially harmful? Conclusion Although corticosteroid bursts have potential for improving outcomes for many acute illnesses, this study shows that the potential harms are not trivial. Reference Yao TC, Wang JY, Chang SM, et al.…
Read More
 No difference in resolution of urinary tract infection symptoms with 7 vs 14 days of antibiotic therapy among afebrile men
AdARRC™ October 11, 2021 Monday Weekly Update

No difference in resolution of urinary tract infection symptoms with 7 vs 14 days of antibiotic therapy among afebrile men

Question Is 7 days of antibiotic therapy noninferior to 14 days of therapy when treating urinary tract infection symptoms in afebrile men? Conclusion This study found that 7 days of antibiotic therapy with either ciprofloxacin or trimethoprim/sulfamethoxazole is noninferior to…
Read More
 High-frequency spinal cord stimulation improves pain in patients with refractory painful diabetic neuropathy
AdARRC™ October 4, 2021 Monday Weekly Update

High-frequency spinal cord stimulation improves pain in patients with refractory painful diabetic neuropathy

Question Is high-frequency spinal cord stimulation added to conventional medical management effective in alleviating pain in persons with painful diabetic neuropathy refractory to medical therapy? Conclusion Is high-frequency spinal cord stimulation added to conventional medical management effective in alleviating pain…
Read More
 More unfavorable outcomes with 6 weeks versus 12 weeks of oral antibiotic therapy for prosthetic joint infections
AdARRC™ September 27, 2021 Monday Weekly Update

More unfavorable outcomes with 6 weeks versus 12 weeks of oral antibiotic therapy for prosthetic joint infections

Question What is the optimal duration of oral antibiotic therapy after surgical treatment for prosthetic hip or knee joint infections? Conclusion Following surgical treatment for prosthetic joint infections, a 6-week course of oral antibiotic therapy is not as effective as…
Read More
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

AdARRC™

Organising Secretariat

  • K.I.T. Group Middle East FZ LLC
  • Yas Creative Hub, Tower 1
  • P.O. Box: 77893
  • Abu Dhabi, United Arab Emirates

+ 971 2 245 0058
+ 971 55 295 0283
info@adarrc.org
Monday – Friday: 9:00 AM – 06:00 PM (GMT+4)

Important Dates

Registration

  • Early Bird: 04 April 2025
  • Standard: 03 July 2025
  • Late/Onsite: 04 September 2025

Call for Abstracts

  • Submission Opens 16 April 2025
  • Submission Deadline: 15 July 2025
  • Acceptance Notification: 10 August 2025

 

Best Image

  • Submission Opens: 28 April 2025
  • Submission Deadline: 28 July 2025

© 2025 AdARRC™. All rights reserved